Altay Aliyev

Spesialisasi: Clinical oncologist
16 tahun pengalaman
Berbahasa:
Azerbaijani, English, Turkish
Konsultasi online: tersedia
Tempat kerja: Azerbaijão, Bacu, Liv Bona Dea Hospital Baku
Dr. Altay Aliyev Penyakit Dalam dan Onkologi Medis
Dr. Altay Aliyev adalah onkolog klinis di Rumah Sakit Liv Bona Dea, Baku. Beliau berspesialisasi dalam kemoterapi, imunoterapi, dan pengobatan bertarget untuk berbagai jenis kanker. Dr. Aliyev menyelesaikan fellowship sebagai peneliti rekanan di Cleveland Clinic. Beliau menangani kondisi kompleks seperti glioblastoma, kanker payudara metastatik, dan tumor kolorektal.
- Keahlian mencakup kemoterapi sitotoksik, terapi hormon, dan perawatan onkologi paliatif.
- Mempublikasikan penelitian tentang penanda tumor pada kanker tiroid dan kemoterapi kanker payudara.
- Sebelumnya menjabat sebagai peneliti rekanan di Departemen Endokrinologi Cleveland Clinic.
- Berpraktik di Rumah Sakit Liv Bona Dea, fasilitas terakreditasi JCI di Azerbaijan.

Jelajahi paket bersama Dr. Altay Aliyev

Pilih Prosedur

HIPEC untuk Kanker Peritoneal oleh Spesialis Onkologi Medis — Program 7 Hari

$7,400

per paket

Paket mencakup rangkaian layanan medis standar dari klinik serta manfaat tambahan seperti akomodasi, transfer, dll.

Konsultasi online dengan Altay Aliyev

Mudah dan praktis

100% aman dan rahasia

Harga berdasarkan permintaan

Layanan dokter

Bagaimana pelayanan kami?

1 dari 3

Informasi tentang dokter ini lengkap dan jelas.

Sangat tidak setuju

Sangat setuju

Kualifikasi

Dr. Altay Aliyev is a specialist in internal medicine and medical oncology at Liv Bona Dea Hospital Baku. He completed a research residency at the Cleveland Clinic in the United States. Dr. Aliyev focuses on the early diagnosis, immunotherapy, and targeted treatment of solid tumors.

Specialization and Clinical Focus

Dr. Aliyev treats oncological conditions using modern systemic therapies. He specializes in creating treatment plans for breast, colon, and prostate cancers. The physician also treats rare malignancies like chordoma, thymoma, and glioblastoma. These therapies include:

Cytotoxic chemotherapy and hormone therapy
Molecularly targeted treatments for metastatic disease
Cancer immunotherapy and palliative care
Treatment of side effects, such as chemotherapy-related arterial issues
Early cancer diagnosis and prevention strategies

Professional Experience

Currently serves as a medical oncologist at Liv Bona Dea Hospital Baku.
2016–2019 — Specialist in medical oncology at Bezmiâlem Foundation University.
2013–2014 — Research Associate at the Cleveland Clinic Endocrinology Department.
2011–2015 — Internal medicine specialist at Istanbul University, Istanbul Faculty of Medicine.

Education and Academic Background

2004–2010 — Istanbul University, Istanbul Faculty of Medicine — Degree in medicine.
2015 — Internal Medicine Specialty, Istanbul Faculty of Medicine.
2019 — Medical Oncology Subspecialty, Bezmiâlem Foundation University.

Research and Scientific Contributions

The doctor conducts research on tumor markers and treatment outcomes. He investigated the prognostic value of monocyte counts in mantle cell lymphoma. His research also covers the effects of chemotherapy on lipid profiles and anthropometric parameters. Dr. Aliyev has published over five original studies in international medical journals. These publications include:

"The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer."
"Diagnostic accuracy of circulating thyrotropin receptor messenger RNA in thyroid cytology," published in Surgery.
"Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients."
"Real-life practice outcomes of Pertuzumab and Trastuzumab-based treatment for breast cancer."
"Usefulness of serum M30 and M65 levels to predict chemotherapy response."
"Circulating Thyroid-Stimulating Hormone Receptor Messenger RNA as a Marker of Tumor Aggressiveness in Patients with Papillary Thyroid Microcarcinoma."
"Prognostic impact of primary tumor location on survival in metastatic colorectal cancer patients: A single center experience."